Australia’s largest clinical trial is a step closer to revealing in 2018 whether healthy older people should or should not take aspirin to prevent or delay cardiovascular disease (heart attack and stroke), dementia, depression and some types of cancers. ASPREE (ASPirin in Reducing Events in the Elderly), a randomised, placebo controlled trial in older people, today reached its recruitment target of 19,000 participants in Australia and the US.
Led by Monash University and the Berman Center for Outcomes and Clinical Research in the US, the ASPREE trial will measure extended years of living free from physical and cognitive disability, to determine the benefits versus the risks of daily low-dose aspirin.
Read more >>
No comments:
Post a Comment